181 related articles for article (PubMed ID: 16320724)
1. Upregulation of TRAIL expression on human T lymphocytes by interferon beta and glatiramer acetate.
Arbour N; Rastikerdar E; McCrea E; Lapierre Y; Dörr J; Bar-Or A; Antel JP
Mult Scler; 2005 Dec; 11(6):652-7. PubMed ID: 16320724
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.
Karandikar NJ; Crawford MP; Yan X; Ratts RB; Brenchley JM; Ambrozak DR; Lovett-Racke AE; Frohman EM; Stastny P; Douek DC; Koup RA; Racke MK
J Clin Invest; 2002 Mar; 109(5):641-9. PubMed ID: 11877472
[TBL] [Abstract][Full Text] [Related]
4. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis.
Putheti P; Soderstrom M; Link H; Huang YM
J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106
[TBL] [Abstract][Full Text] [Related]
5. TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response.
López-Gómez C; Oliver-Martos B; Pinto-Medel MJ; Suardiaz M; Reyes-Garrido V; Urbaneja P; Fernández Ó; Leyva L
J Neurol Neurosurg Psychiatry; 2016 Feb; 87(2):130-7. PubMed ID: 25736057
[TBL] [Abstract][Full Text] [Related]
6. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.
Kayagaki N; Yamaguchi N; Nakayama M; Eto H; Okumura K; Yagita H
J Exp Med; 1999 May; 189(9):1451-60. PubMed ID: 10224285
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
8. Induction of costimulation of human CD4 T cells by tumor necrosis factor-related apoptosis-inducing ligand: possible role in T cell activation in systemic lupus erythematosus.
Tsai HF; Lai JJ; Chou AH; Wang TF; Wu CS; Hsu PN
Arthritis Rheum; 2004 Feb; 50(2):629-39. PubMed ID: 14872508
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
[TBL] [Abstract][Full Text] [Related]
10. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
Herbeuval JP; Hardy AW; Boasso A; Anderson SA; Dolan MJ; Dy M; Shearer GM
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13974-9. PubMed ID: 16174727
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.
Horani A; Muhanna N; Pappo O; Melhem A; Alvarez CE; Doron S; Wehbi W; Dimitrios K; Friedman SL; Safadi R
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G628-38. PubMed ID: 17038628
[TBL] [Abstract][Full Text] [Related]
12. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
[TBL] [Abstract][Full Text] [Related]
13. Impact of immunomodulatory treatment on leukocyte cytokine production in multiple sclerosis patients and healthy donors.
Reske D; Thomas AV; Petereit HF; Fink GR; Schroeter M
Neuroimmunomodulation; 2009; 16(6):385-91. PubMed ID: 19609087
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells.
Ragheb S; Abramczyk S; Lisak D; Lisak R
Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193
[TBL] [Abstract][Full Text] [Related]
15. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.
Putheti P; Pettersson A; Soderstrom M; Link H; Huang YM
J Clin Immunol; 2004 Mar; 24(2):155-61. PubMed ID: 15024182
[TBL] [Abstract][Full Text] [Related]
16. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta.
Hussien Y; Sanna A; Söderström M; Link H; Huang YM
Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis.
Biegler BW; Yan SX; Ortega SB; Tennakoon DK; Racke MK; Karandikar NJ
J Neuroimmunol; 2006 Nov; 180(1-2):159-71. PubMed ID: 16935352
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis of CD4+ T cells by immunomodulatory therapy of multiple sclerosis with glatiramer acetate.
Rieks M; Hoffmann V; Aktas O; Juschka M; Spitzer I; Brune N; Schimrigk S; Przuntek H; Pöhlau D
Eur Neurol; 2003; 50(4):200-6. PubMed ID: 14634263
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Tennakoon DK; Mehta RS; Ortega SB; Bhoj V; Racke MK; Karandikar NJ
J Immunol; 2006 Jun; 176(11):7119-29. PubMed ID: 16709875
[TBL] [Abstract][Full Text] [Related]
20. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
